Show simple item record

dc.contributor.authorUddin, Md Sahab
dc.contributor.authorKabir, Md Tanvir
dc.contributor.authorRahman, Md Motiar
dc.contributor.authorMathew, Bijo
dc.contributor.authorShah, Muhammad Ajmal
dc.contributor.authorAshraf, Ghulam Md
dc.date.accessioned2022-05-03T01:16:17Z
dc.date.available2022-05-03T01:16:17Z
dc.date.issued2020
dc.identifier.issn0022-3573
dc.identifier.doi10.1111/jphp.13244
dc.identifier.urihttp://hdl.handle.net/10072/414248
dc.description.abstractObjectives: Alzheimer’s disease (AD) is one of the most prevalent neurodegenerative disorders and a well-recognized cause of dementia with ageing. In this review, we have represented the ChE and MAO inhibitory potential of TV 3326 against AD based on current scientific evidence. Key findings: The aetiology of AD is quite complex and not completely understood. However, it has been observed that AD involves the deposition of abnormal amyloid beta (Aβ), along with hyperphosphorylation of tau, oxidative stress, low acetylcholine (ACh) level and biometal dyshomeostasis. Due to the complex nature of AD aetiology, active research is required in the areas of development of multitarget drugs with 2 or more complementary biological functions, as they might represent significant progress in the AD treatment. Interestingly, it has been found that TV 3326 (i.e. ladostigil) is regarded as a novel therapeutic agent since it has the potential to cause inhibition of monoamine oxidase (MAO) A and B, and acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in the brain. Furthermore, it has the capacity to reverse memory impairments, which further suggests the ability of this drug to elevate cholinergic activity in the brain. Summary: TV 3326 can avert oxidative–nitrative stress and gliosis. It has also been confirmed that TV 3326 contains neuroprotective and anti-apoptotic properties. Therefore, this distinctive combined inhibition of ChE and MAO along with its neuroprotective property makes TV 3326 a useful drug in the treatment of AD.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherWiley
dc.relation.ispartofpagefrom1001
dc.relation.ispartofpageto1012
dc.relation.ispartofissue8
dc.relation.ispartofjournalJournal of Pharmacy and Pharmacology
dc.relation.ispartofvolume72
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchcode3214
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsPharmacology & Pharmacy
dc.subject.keywordsAlzheimer's disease
dc.subject.keywordscholinesterase inhibitor
dc.subject.keywordsladostigil
dc.subject.keywordsmonoamine oxidase inhibitor
dc.subject.keywordsTV 3326
dc.titleTV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationUddin, MS; Kabir, MT; Rahman, MM; Mathew, B; Shah, MA; Ashraf, GM, TV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology, Journal of Pharmacy and Pharmacology, 2020, 72 (8), pp. 1001-1012
dcterms.dateAccepted2020-02-09
dc.date.updated2022-04-27T22:28:07Z
gro.hasfulltextNo Full Text
gro.griffith.authorKabir, Md. Tanvir


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record